PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, announced today that members of the management team will participate at the 2017 RBC Capital Markets Global Healthcare Conference to be held on February 22-23 at the New York Palace in New York City.
Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX is scheduled to participate in a fireside chat with an RBCCM healthcare analyst at 1:35 PM (EST) on February 22nd. Additionally, Prof. Ehrlich, along with ABIVAX’s CFO and CMO, Didier Blondel and Jean-Marc Steens, M.D., will be available for one-on-one meetings with interested investors over the course of the conference.
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on targeting the
immune system to eliminate viral disease. ABIVAX leverages three
technology platforms for drug discovery: an antiviral, an immune
enhancement, and a polyclonal antibody platform. ABX464, its most
advanced compound, is currently in Phase II clinical trials for
providing a functional cure for patients with HIV/AIDS. It is a
first-in-class oral small antiviral molecule which blocks HIV
replication through a unique mechanism of action and also has a strong
anti-inflammatory effect. In addition, ABIVAX is advancing a clinical
stage immune enhancer as well as multiple preclinical candidates against
additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several
of these compounds are planned to enter clinical development within the
next 18 months. ABIVAX is listed on Euronext compartment B (ISIN:
FR0012333284 – Mnémo: ABVX).
More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_